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A B S T R A C T
A 23-year-old man was referred to our center with hematuria and hemolysis. The patient had undergone
mitral and tricuspid valve replacement 3 months previously. Echocardiography and catheterization
revealed a Gerbode-type ventricular septal defect. A decision was made to occlude the defect
interventionally. The patient’s hematuria ceased immediately after the occlusion of the defect.
<Learning objective: Iatrogenic ventricular septal defects (especially Gerbode-type) are relatively rare
complications after valvular surgery. Correction of such defects can be done both surgically and
interventionally, but since the risk of another operation for correction is high, percutaneous ventricular
septal defect closure is usually the preferred treatment option. Using an appropriate approach will
increase the success rate.>
 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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The transcatheter closure of ventricular septal defects (VSDs) is
a well-described method for the closure of certain types of VSDs.
Gerbode-type defects are more complex for interventional
approaches, and there is a paucity of information in the existing
literature on intervention for iatrogenic Gerbode defects [1,3].
We herein introduce a patient with an iatrogenic Gerbode defect
after mitral and tricuspid valve replacements (as the second open
heart surgery) whom was hematuric due to hemolysis.
Case report
A 23-year-old man presented with hematuria 3 months after
the second valvular surgery. Hemolysis was determined as the
etiology of the hematuria after paraclinical evaluation, revealing
hemoglobin of 8.1 with normal mean corpuscular volume (MCV)
and mean corpuscular hemoglobin (MCH) along with hemoglo-
binuria, raised lactate dehydrogenase (LDH: 680 IU/L) and indirect
bilirubin (Indirect bili.: 3 mg/dL), and presence of schistocytes
(1.2%) in the peripheral blood smear (compatible with moderate
hemolysis). Physical examination revealed loud pansystolic* Corresponding author at: Department of Interventional Cardiology, Shahid
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closure clicks of the mechanical valve. Transesophageal echocar-
diography showed a Gerbode-type VSD with size about 6.5–7 mm
and high pressure gradient flow (105.5 mmHg) (Fig. 1). Left
ventricle (LV) and right ventricle (RV) sizes were normal, and
there was mild RV systolic dysfunction. The mechanical prosthetic
valve which was placed in mitral position was normal but
moderate tricuspid valve regurgitation (TR) was present. The
Gerbode defect was considered as the cause of the hemolysis (i.e.
traumatic hemolysis). The Qp/Qs was estimated 1.1 by catheteri-
zation and the pulmonary artery pressure was 30/10 mmHg. LV
contrast injection illustrated blood shunting from the LV to the
right atrium (RA) with a normal LV systolic function. We decided
to close the defect by percutaneous interventional approach.
Given the defect size and shape, an Amplatzer duct occluder,
size 10–8, was chosen. We tried antegrade approach and used a 7 F
sheath (Fig. 2). Under fluoroscopic and transesophageal echocar-
diography guidance, the sheath tip was positioned at the correct
location in the LV. By pulling back the sheath, the disc of the device
was expanded up to its tubular stent part. The whole system was
then repositioned and withdrawn slightly, enabling the stent part
of the device to close the defect with the disc lying on the LV side
of the defect near the left ventricular outflow tract (LVOT). At this
point, multiple LV contrast injections along with transesophageal
echocardiography guidance confirmed the correct position of the
device and absence of any blood shunting and impingement of
nearby structures. Pulling back the introducer sheath the device reserved.
Fig. 1.
(A and B) Transesophageal echocardiography (TEE) short-axis view (2D and color Doppler) shows a defect between LVOT and RA. (C and D) Off-axis view (2D and
color Doppler) shows a tortuous tract between both cavities. (E) Color Doppler of this off axis view shows turbulent high flow through the defect. (F) Continuous
wave Doppler shows there is a high pressure gradient flow through the defect (105 mmHg).
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shunt (Fig. 2).
After the procedure, the patient had a stable hospital course
and the hemolysis and resultant hematuria subsided with normal
long-term follow-up.
Discussion
Although iatrogenic Gerbode defects are rare, the hemodynam-
ic consequences of such defects can cause progressive congestive
heart failure with high mortality rates if left uncorrected. So it
appears that the correction of this type of defect, irrespective of
clinical symptoms and shunt degree, is necessary [2]. To avoid
creating this defect (i.e. as a prophylactic measure), the operating
surgeon must exercise caution so as not to injure the membranous
septum during aortic or mitral valve replacement, especially if vast
calcium debridement is needed. Also the surgeon should examine
the IVS to find a thrill that is a sign of such defect, if it was created
during the procedure [2]. These patients are at a relatively high risk
for surgical correction since they have undergone previously a
surgical operation with a relatively short time interval for the
second operation.
Rothman et al. reported a patient with iatrogenic Gerbode
defect who presented with dyspnea 6 months after a second
cardiac surgery for mitral valve replacement [1]. They used an
Amplatzer duct occluder (size 10–8) and chose the retrograde
approach. In contrast to our patient, in their case hemolysis had
started after device placement which was resolved spontaneously.
In two cases reported by Matsumoto et al. [4], non-Gerbode-type
iatrogenic VSDs after surgical aortic valve replacement were
corrected interventionally. The authors mentioned that the
deployment of the device in such defects was not possible via
the anterograde approach, because of the angulated anatomy and
trabeculation of the RV; although retrograde approach could not
be possible because of presence of mechanical prosthetic valve inaortic position, so the trans-septal approach was tried. In this
approach, after atrial septostomy was performed and a balloon
floating catheter was placed in the LV. The catheter was then
crossed through the VSD and entered into the PA. Then a wire was
passed into the PA and snared in the PA to form a venous arterial
venous loop to insert a sheath and deploy the device over the
venous side.
Traditionally surgery has been the treatment of choice for
iatrogenic non-coronary fistulous pathways. Because percutane-
ous repair is considered as an off-label method for these defects,
there is no consensus on the optimal approach. Appropriate sizing
of the device and device type, choosing the best approach for
delivery system and positioning the device are the most important
issues. As Gerbode defects are relatively longer and are more
probable to be tortuous than muscular and membranous types
the Amplatzer duct occluder is more suitable than VSD occluder
devices in such defects. Also a sizing balloon can be used in order to
find the most accurate device size although it is not mandated
because it can injure adjacent structures by itself. Choosing
between antegrade or retrograde approaches for the delivery
system depends on operator’s experience, anatomy of the defect,
and patient’s peripheral vascular conditions. We opted for
antegrade approach to avoid snaring, which may cause damage
to the nearby structures due to tension in the arteriovenous loop.
In our opinion, the antegrade approach should be considered as
the first method, and only if this approach fails should we
contemplate the retrograde approach as a second option (consid-
ering the presence of certain types of prosthetic aortic valves).
Multiple contrast injections along with TEE guidance can reduce
the risk of device malposition and its consequences, valvular
regurgitation, obstruction of major veins (IVC or SVC), erosion of
nearby structures, and hemolytic anemia. One potentially lethal
condition is device loss which can cause obstruction of blood flow
of large vessels and even LVOT. This can also be avoided by
appropriate sizing and placement of the device.
Fig. 2.
(A and B) LV and LVOT contrast injection. (C) A 7 F long sheath passed
the defect. (D–F) Device deployment.
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initiated after the VSD closure. Also hemolysis after prosthetic
valve implantation (whether bioprosthetic or mechanical valves) is
one of the major possible complications. Therefore, although our
patient’s hemolysis was relieved after the procedure, there was
an unrecognized probability of the aggravation of hemolysis
after the procedure. Indeed, the appropriate sizing and placing of
the device to avoid residual shunting and flow turbulence nearby
may contribute to the elimination of hemolysis.
Conclusion
Iatrogenic Gerbode defects must be occluded. The transcatheter
correction of an iatrogenic Gerbode defect can be done by an
experienced operator via the antegrade approach, considering the
same rules and techniques for the occlusion of congenital muscular
and membranous VSDs.
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